Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).-论文-万方医学网

第一作者： Loic,Lebellec

第一单位： Department of Medical Oncology, Centre Oscar Lambret, Lille, France.

作者： Loic,Lebellec ^[1] ; François,Bertucci ^[2] ; Emmanuelle,Tresch-Bruneel ^[3] ; Emmanuelle,Bompas ^[4] ; Yves,Toiron ^[5] ; Luc,Camoin ^[5] ; Olivier,Mir ^[6] ; Valerie,Laurence ^[7] ; Stephanie,Clisant ^[8] ; Emilie,Decoupigny ^[3] ; Jean-Yves,Blay ^[8] ; Anthony,Goncalves ^[9] ; Nicolas,Penel ^[5]

作者单位： Department of Medical Oncology, Centre Oscar Lambret, Lille, France. ^[1] Department of Medical Oncology, Institut Paoli-Calmette, Marseille, France. ^[2] SIRIC OncoLille, Clinical Research and Methodological Platform, Lille, France. ^[3] Department of Medical Oncology, Centre René Gauducheau, Nantes, France. ^[4] Department of Molecular Pharmacology, Cancer Research Center of Marseille, Institut Paoli Calmettes, Marseille, France. ^[5] Department of Medical Oncology, Gustave Roussy, Villejuif, France. ^[6] Department of Medical Oncology, Institut Curie, Paris, France. ^[7] Clinical Research Unit, Centre Oscar Lambret, Lille, France. ^[8] Department of Medical Oncology, Centre Léon Bérard, Lyon, France. ^[9]

主题词成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤药(Antineoplastic Agents);脊索瘤(Chordoma);临床试验, Ⅱ期(主题)(Clinical Trials, Phase II as Topic);综合疗法(Combined Modality Therapy);女(雌)性(Female);人类(Humans);Kaplan-Meiers评估(Kaplan-Meier Estimate);男(雄)性(Male);膜蛋白质类(Membrane Proteins);中年人(Middle Aged);肿瘤转移(Neoplasm Metastasis);肿瘤分期(Neoplasm Staging);烟酰胺(Niacinamide);苯脲化合物(Phenylurea Compounds);预后(Prognosis);蛋白激酶抑制剂(Protein Kinase Inhibitors);血管内皮生长因子A(Vascular Endothelial Growth Factor A)

DOI 10.18632/oncotarget.12172

PMID 27659533

发布时间 2018-12-02

检索历史清除

Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).

Oncotarget

相似文献

Oncotarget

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).

Oncotarget

相似文献

Oncotarget

相关期刊

检索历史清除